Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP-2) trial: study protocol for a randomized controlled trial

详细信息    查看全文

• 作者：Daniel F McAuley (1) (2) (3)
  John G Laffey (4)
  Cecilia M O’Kane (1)
  Mark Cross (1) (2)
  Gavin D Perkins (5)
  Lynn Murphy (3)
  Christine McNally (3)
  Grainne Crealey (3)
  Michael Stevenson (3)
  
• 关键词：Simvastatin ; Acute lung injury ; Acute respiratory distress syndrome
• 刊名：Trials
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：13
• 期：1
• 全文大小：439KB
• 参考文献：1. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R: The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. / Am J Respir Crit Care Med 1994, 149:818-24.
  2. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD: Incidence and outcomes of acute lung injury. / N Engl J Med 2005, 353:1685-693. CrossRef
  3. Brun-Buisson C, Minelli C, Bertolini G, Brazzi L, Pimentel J, Lewandowski K, Bion J, Romand JA, Villar J, Thorsteinsson A, Damas P, Armaganidis A, Lemaire F, ALIVE Study Group: Epidemiology and outcome of acute lung injury in European intensive care units. Results from the ALIVE study. / Intensive Care Med 2004, 30:51-1. CrossRef
  4. Irish Critical Care Trials Group: Acute lung injury and the acute respiratory distress syndrome in Ireland: a prospective audit of epidemiology and management. / Crit Care 2008, R30.
  5. Erickson SE, Martin GS, Davis JL, Matthay MA, Eisner MD: Recent trends in acute lung injury mortality: 1996-005. / Crit Care Med 2009, 37:1574-579. CrossRef
  6. Herridge MS, Tansey CM, Matte A, Tomlinson G, Diaz-Granados N, Cooper A, Guest CB, Mazer CD, Mehta S, Stewart TE, Kudlow P, Cook D, Slutsky AS, Cheung AM, Canadian Critical Care Trials Group: Functional disability 5 years after acute respiratory distress syndrome. / N Engl J Med 2011, 364:1293-304. CrossRef
  7. Rossi C, Simini B, Brazzi L, Rossi G, Radrizzani D, Iapichino G, Bertolini G: Variable costs of ICU patients: a multicenter prospective study. / Intensive Care Med 2006, 32:545-52. CrossRef
  8. Cheung AM, Tansey CM, Tomlinson G, Diaz-Granados N, Matte A, Barr A, Mehta S, Mazer CD, Guest CB, Stewart TE, Al-Saidi F, Cooper AB, Cook D, Slutsky AS, Herridge MS: Two-year outcomes, health care use, and costs of survivors of acute respiratory distress syndrome. / Am J Respir Crit Care Med 2006, 174:538-44. m.200505-693OC">CrossRef
  9. Craig T, O'Kane CM, McAuley DF: Potential mechanisms by which statins modulate pathogenic mechanisms important in the development of acute lung injury. In / 27th Yearbook of Intensive Care and Emergency Medicine. Edited by: Vincent JL. Springer-Verlag, Berlin; 2007:276-88.
  10. Shyamsundar M, McKeown S, O’Kane C, Craig T, Brown V, Thickett DR, Matthay MA, Taggart C, Backmann J, Elborn JS, McAuley DF: Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. / Am J Respir Crit Care Med 2009, 179:1107-114. m.200810-1584OC">CrossRef
  11. Craig TR, Duffy MJ, Shyamsundar M, McDowell C, O'Kane CM, Elborn JS, McAuley DF: A randomized clinical trial of hydroxymethylglutaryl- coenzyme a reductase inhibition for acute lung injury (The HARP Study). / Am J Respir Crit Care Med 2011, 183:620-26. m.201003-0423OC">CrossRef
  12. Schulz KF, Altman DG, Moher D: CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. / Trials 2010, 11:32. CrossRef
  13. Gao Smith F, Perkins GD, Gates S, Young D, McAuley DF, Tunnicliffe W, Khan Z, Lamb SE: Effect of intravenous beta-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. / Lancet 2012, 379:229-35. CrossRef
  14. Felton TW, Sander R, Al-Aloul M, Dark P, Bentley AM: Can a score derived from the Critical Care Minimum Data Set be used as a marker of organ dysfunction? - a pilot study. / BMC Res Notes 2009, 2:77. CrossRef
  15. The EuroQol Group: EuroQol–a new facility for the measurement of health-related quality of life. / Health Policy 1990, 16:199-08. CrossRef
  16. The ARDS Network investigators: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. / N Eng J Med 2000, 342:1301-308. CrossRef
  17. Matthay MA, Brower RG, Carson S, Douglas IS, Eisner M, Hite D, Holets S, Kallet RH, Liu KD, MacIntyre N, Moss M, Schoenfeld D, Steingrub J, Thompson BT: Randomized, placebo-controlled clinical trial of an aerosolized beta-agonist for treatment of acute lung injury. / Am J Respir Crit Care Med 2011, 184:561-68. m.201012-2090OC">CrossRef
  18. Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M, Schoenfeld D, Thompson BT: Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. / N Engl J Med 2004, 351:327-36. CrossRef
  19. Mercat A, Richard JC, Vielle B, Jaber S, Osman D, Diehl JL, Lefrant JY, Prat G, Richecoeur J, Nieszkowska A, Gervais C, Baudot J, Bouadma L, Brochard L, Expiratory Pressure (Express) Study Group: Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. / JAMA 2008, 299:646-55. ma.299.6.646">CrossRef
  20. Kor DJ, Iscimen R, Yilmaz M, Brown MJ, Brown DR, Gajic O: Statin administration did not influence the progression of lung injury or associated organ failures in a cohort of patients with acute lung injury. / Intensive Care Med 2009, 35:1039-046. CrossRef
  21. Harvey S, Harrison DA, Singer M, Ashcroft J, Jones CM, Elbourne D, Brampton W, Williams D, Young D, Rowan K: Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. / Lancet 2005, 366:472-77. CrossRef
  22. Excellence NIfHaC: / Guide to the Methods of Technology Appraisal. NICE, London; 2008.
  23. Curtis LA: / Unit Costs of Health and Social Care 2007. Personal Social Services Research Unit, University of Kent, Canterbury; 2007.
  
• 作者单位：Daniel F McAuley (1) (2) (3)
  John G Laffey (4)
  Cecilia M O’Kane (1)
  Mark Cross (1) (2)
  Gavin D Perkins (5)
  Lynn Murphy (3)
  Christine McNally (3)
  Grainne Crealey (3)
  Michael Stevenson (3)
  
  1. Centre for Infection and Immunity, Queen’s University of Belfast, Belfast, BT9 7BL, UK
  2. Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, BT12 6BA, UK
  3. Clinical Research Support Centre, Royal Victoria Hospital, Belfast, BT12 6BA, UK
  4. Department of Anaesthesia, Clinical Sciences Institute, National University of Ireland, Galway, Ireland
  5. Warwick Medical School Clinical Trials Unit, University of Warwick, Warwick, CV4 7AL, UK
  

文摘

Background Acute lung injury (ALI) is a common devastating clinical syndrome characterized by life-threatening respiratory failure requiring mechanical ventilation and multiple organ failure. There are in vitro, animal studies and pre-clinical data suggesting that statins may be beneficial in ALI. The Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP-2) trial is a multicenter, prospective, randomized, allocation concealed, double-blind, placebo-controlled clinical trial which aims to test the hypothesis that treatment with simvastatin will improve clinical outcomes in patients with ALI. Methods/Design Patients fulfilling the American-European Consensus Conference Definition of ALI will be randomized in a 1:1 ratio to receive enteral simvastatin 80 mg or placebo once daily for a maximum of 28 days. Allocation to randomized groups will be stratified with respect to hospital of recruitment and vasopressor requirement. Data will be recorded by participating ICUs until hospital discharge, and surviving patients will be followed up by post at 3, 6 and 12 months post randomization. The primary outcome is number of ventilator-free days to day 28. Secondary outcomes are: change in oxygenation index and sequential organ failure assessment score up to day 28, number of non pulmonary organ failure free days to day 28, critical care unit mortality; hospital mortality; 28 day post randomization mortality and 12 month post randomization mortality; health related quality of life at discharge, 3, 6 and 12 months post randomization; length of critical care unit and hospital stay; health service use up to 12 months post-randomization; and safety. A total of 540 patients will be recruited from approximately 35 ICUs in the UK and Ireland. An economic evaluation will be conducted alongside the trial. Plasma and urine samples will be taken up to day 28 to investigate potential mechanisms by which simvastatin might act to improve clinical outcomes. Trial registration Current Controlled Trials ISRCTN88244364.